What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
The scientist’s investigation covers issues in Hepatocellular carcinoma, Internal medicine, Carcinoma, Radiology and Sorafenib.
His studies deal with areas such as Survival rate, Surgery, Pathology and Radiofrequency ablation as well as Hepatocellular carcinoma.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo and Oncology.
His Carcinoma research incorporates themes from Lipiodol, Cancer research, Retrospective cohort study and Prospective cohort study.
His Radiology study integrates concerns from other disciplines, such as Differential diagnosis and Pancreas.
His work on Lenvatinib as part of general Sorafenib study is frequently linked to In patient, bridging the gap between disciplines.
His most cited work include:
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (1507 citations)
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial (1397 citations)
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (1199 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Hepatocellular carcinoma, Oncology, Radiology and Gastroenterology are his primary areas of study.
Internal medicine is closely attributed to Placebo in his research.
His Hepatocellular carcinoma research integrates issues from Carcinoma and Surgery.
He has researched Oncology in several fields, including Pembrolizumab, Cancer, Nivolumab and Regorafenib.
His work on Radiofrequency ablation expands to the thematically related Radiology.
The concepts of his Gastroenterology study are interwoven with issues in Hepatitis C and Hazard ratio.
He most often published in these fields:
- Internal medicine (49.49%)
- Hepatocellular carcinoma (48.89%)
- Oncology (24.31%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (49.49%)
- Hepatocellular carcinoma (48.89%)
- Oncology (24.31%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Hepatocellular carcinoma, Oncology, In patient and Sorafenib.
The various areas that Masatoshi Kudo examines in his Internal medicine study include Gastroenterology and Placebo.
Masatoshi Kudo works mostly in the field of Hepatocellular carcinoma, limiting it down to topics relating to Pembrolizumab and, in certain cases, Cancer research.
His biological study deals with issues like Nivolumab, which deal with fields such as Ipilimumab.
His In patient research spans across into fields like Stent and Radiology.
His studies in Sorafenib integrate themes in fields like Regorafenib and Cohort study.
Between 2018 and 2021, his most popular works were:
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma (529 citations)
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (410 citations)
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial (264 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
His scientific interests lie mostly in Hepatocellular carcinoma, Internal medicine, Oncology, Sorafenib and Lenvatinib.
The Hepatocellular carcinoma study combines topics in areas such as Pembrolizumab, Clinical trial and Carcinoma.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
His research on Oncology also deals with topics like
- Systemic therapy which connect with Targeted therapy,
- Phases of clinical research, which have a strong connection to Accelerated approval.
His Sorafenib study which covers Hazard ratio that intersects with Subset Analysis and Liver cancer.
His Lenvatinib research is multidisciplinary, incorporating elements of Liver function, Regorafenib and Multikinase inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
